Primary cutaneous ALCL represents an indolent cutaneous T-cell lymphoproliferative disorder that typically demonstrates an alpha-beta T-cell receptor lineage. However, oncologists occasionally encounter atypical variants that challenge routine diagnostic algorithms. Recently, pathologists identified a rare manifestation showing a gamma-delta T-cell receptor phenotype alongside an unbalanced DUSP22-IRF4 chromosomal rearrangement. Although gamma-delta cutaneous lymphomas usually portend an aggressive clinical trajectory, primary cutaneous ALCL with this phenotype maintains a remarkably indolent course. Therefore, clinicians must recognize these molecular nuances to avoid unwarranted chemotherapy.

Clinical Presentation and Course of Primary Cutaneous ALCL

Most patients with primary cutaneous ALCL present with solitary or localized nodules, tumors, or ulcerating plaques. In addition, these lesions typically arise on the head, neck, or trunk of older adults. Although spontaneous partial regression occurs in some individuals, recurrence remains a frequent clinical reality. For example, clinicians recently documented an elderly male who achieved durable complete remission following local radiotherapy. However, five years later, he developed an asymptomatic recurrent nodule on his neck.

Furthermore, late localized cutaneous recurrences do not signify systemic dissemination. Dermatologists frequently manage repeated cutaneous recurrences over several decades without observing visceral or nodal involvement. Therefore, clinicians must maintain diligent clinical surveillance following primary treatment. Notably, recognizing a recurrence as a localized cutaneous process prevents unwarranted systemic workups or excessive therapeutic interventions. In addition, prompt clinical identification allows early local therapy, which mitigates tumor growth and preserves cosmetic outcomes. Consequently, longitudinal clinical follow-up provides vital reassurances regarding overall survival and quality of life.

Histopathological and Immunohistochemical Hallmarks

Histological examination reveals a dense, non-epidermotropic dermal infiltrate composed of cohesive sheets of medium to large atypical lymphoid cells. Moreover, these neoplastic cells display pleomorphic, horseshoe-shaped nuclei, prominent nucleoli, and abundant amphophilic cytoplasm. Pathologists routinely observe uniform, strong membranous and Golgi-zone immunoreactivity for CD30 across the entire tumoral population.

However, diagnostic dilemmas emerge when evaluating T-cell receptor expression. Most cutaneous cases demonstrate an alpha-beta lineage, but rare tumors express TCR-gamma-delta and lack TCR-beta. In addition, neoplastic cells frequently lack pan-T-cell markers like CD7, CD4, and CD8. Importantly, ALK staining remains consistently negative, which definitively rules out systemic ALK-positive lymphoma. Pathologists also assess LEF1, TIA-1, and p-STAT3 to refine the classification. Strong LEF1 positivity, absent TIA-1, and predominantly negative p-STAT3 characterize this unique variant. Furthermore, this distinct immunophenotype supports an unbalanced DUSP22 rearrangement, guiding clinicians toward an accurate and reassuring diagnosis.

Molecular Insights: DUSP22-IRF4 Rearrangements

Fluorescence in situ hybridization often detects structural genomic alterations at chromosome 6p25.3. Specifically, rearrangements involving DUSP22 and IRF4 occur in approximately twenty to thirty percent of cutaneous CD30-positive lymphoproliferative disorders. Furthermore, geneticists distinguish balanced translocations from unbalanced rearrangements through specialized break-apart probe assays.

Interestingly, unbalanced DUSP22 rearrangements demonstrate distinct biological characteristics. These genetic events lead to the downregulation of DUSP22, which encodes a dual-specificity phosphatase that inhibits T-cell receptor signaling. As a result, T cells lose negative regulation and sustain proliferative pathways. Furthermore, these tumors exhibit low cytotoxic marker expression and minimal STAT3 activation. In contrast to systemic ALK-negative lymphomas where DUSP22 translocations predict favorable chemotherapy responses, cutaneous neoplasms demonstrate uniformly indolent behavior regardless of this genomic rearrangement. Therefore, molecular testing primarily confirms diagnostic lineage rather than altering standard prognostic expectations. Additionally, identifying these chromosomal alterations eliminates diagnostic uncertainty when atypical immunophenotypes arise.

Differentiating Indolent Disease from Aggressive Mimics

The convergence of a TCR-gamma-delta phenotype with large cell morphology poses a formidable diagnostic challenge. Specifically, pathologists must rigorously differentiate this indolent entity from primary cutaneous gamma-delta T-cell lymphoma. That aggressive malignancy rapidly invades subcutaneous fat and causes systemic deterioration. However, primary cutaneous gamma-delta T-cell lymphoma typically presents with cytotoxic molecules like TIA-1, granzyme B, and perforin, while lacking uniform CD30 positivity.

In addition, dermatopathologists must exclude systemic ALK-negative ALCL with secondary skin involvement. Patients with systemic disease generally exhibit prominent constitutional symptoms, extensive lymphadenopathy, and elevated lactate dehydrogenase levels. Therefore, complete staging with contrast-enhanced computed tomography or PET-CT is essential. Pathologists also consider transformed mycosis fungoides and lymphomatoid papulosis during the evaluation. Fortunately, combining clinical presentation with LEF1 expression and DUSP22 status enables pathologists to establish the indolent nature of the disease confidently. Consequently, interdisciplinary consensus prevents dangerous therapeutic misadventures.

Therapeutic Implications and Long-Term Management

Because primary cutaneous ALCL exhibits indolent biological behavior, clinicians prioritize organ-sparing, conservative interventions. Local radiotherapy serves as the definitive standard of care for solitary or localized recurrent lesions. Radiation oncologists typically administer doses between thirty and thirty-six Gray, which yields complete response rates exceeding ninety-five percent. Alternatively, surgical excision represents an excellent option for easily resectable solitary nodules.

Furthermore, physicians should avoid multi-agent systemic chemotherapy regimens, such as CHOP, because these regimens inflict unnecessary toxicity without improving survival. If widespread multifocal cutaneous lesions emerge, oncologists prefer low-dose oral methotrexate, retinoids, or phototherapy. Moreover, targeted therapies have expanded modern management strategies. For example, brentuximab vedotin, an antibody-drug conjugate targeting CD30, offers robust efficacy in refractory cutaneous disease. In addition, close collaboration between dermatologists and oncologists ensures minimal treatment-related morbidity. Ultimately, maintaining conservative management preserves tissue function while securing superb long-term survival for affected patients.

How does TCR-gamma-delta expression affect prognosis in primary cutaneous ALCL?

Although cytotoxic gamma-delta T-cell lymphomas generally exhibit an aggressive clinical course, primary cutaneous ALCL retaining this phenotype demonstrates a favorable prognosis. Therefore, oncologists must not equate gamma-delta expression alone with high-grade systemic behavior. In this unique setting, clinical staging and comprehensive histological evaluation supersede immunophenotype in predicting outcome. Consequently, clinicians can safely avoid aggressive systemic polychemotherapy, opting instead for localized interventions such as targeted radiotherapy or surgical excision.

Why is DUSP22-IRF4 testing essential in CD30-positive lymphoproliferative disorders?

DUSP22-IRF4 rearrangements help pathologists categorize CD30-positive lymphoproliferative disorders accurately. Furthermore, identifying this genetic alteration guides risk stratification and distinguishes cutaneous disease from systemic ALK-negative anaplastic lymphomas. The presence of unbalanced rearrangements often correlates with specific immunohistochemical profiles, such as LEF1 positivity and p-STAT3 negativity. Consequently, molecular confirmation provides diagnostic clarity, reassures clinicians regarding indolent behavior, and prevents inappropriate escalation to toxic systemic cytotoxic therapy in elderly patients.

What are the primary management options for recurrent localized lesions?

Clinicians manage localized recurrent cutaneous lesions primarily with low-dose local radiation therapy or complete surgical excision. Furthermore, these conservative approaches provide excellent local control and spare patients unnecessary systemic toxicities. However, if multifocal relapses occur, oncologists may administer low-dose methotrexate or targeted agents like brentuximab vedotin. Therefore, multidisciplinary teams tailor therapy according to disease extent, patient age, and performance status while maintaining routine long-term dermatologic surveillance.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Ibrahim E et al. Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma With T-Cell Receptor-ϒδ Phenotype and DUSP22-IRF4 Unbalanced Rearrangement: A Rare and Diagnostically Challenging Presentation. Am J Dermatopathol. 2026 Sep 09. doi: 10.1097/DAD.0000000000003431. PMID: 42715545.
2. Kempf W, Mitteldorf C. CD30-positive cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies. Haematologica. 2019;104(2):226-235.
3. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714.